Acumen Pharmaceuticals Inc (ABOS) - Total Liabilities
Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) has total liabilities worth $46.15 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Acumen Pharmaceuticals Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Acumen Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Acumen Pharmaceuticals Inc (ABOS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Acumen Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Acumen Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quarterhill Inc
TO:QTRH
|
Canada | CA$104.18 Million |
|
Train Alliance Sweden AB Series B
ST:TRAIN-B
|
Sweden | Skr785.98 Million |
|
Cystech Electronics Corp
TWO:6651
|
Taiwan | NT$352.87 Million |
|
Alligator Energy Ltd
AU:AGE
|
Australia | AU$5.19 Million |
|
coocon Corp.
KQ:294570
|
Korea | ₩131.44 Billion |
|
Payton -L
TA:PAYT
|
Israel | ILA10.09 Million |
|
Sunjin
KO:136490
|
Korea | ₩799.26 Billion |
|
Tung Thih Electronic Co Ltd
TWO:3552
|
Taiwan | NT$6.26 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Acumen Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Acumen Pharmaceuticals Inc (ABOS) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acumen Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acumen Pharmaceuticals Inc (2019–2025)
The table below shows the annual total liabilities of Acumen Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $52.40 Million | -8.35% |
| 2024-12-31 | $57.18 Million | +32.50% |
| 2023-12-31 | $43.15 Million | +452.38% |
| 2022-12-31 | $7.81 Million | +51.78% |
| 2021-12-31 | $5.15 Million | -91.83% |
| 2020-12-31 | $63.02 Million | +236.25% |
| 2019-12-31 | $18.74 Million | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement… Read more